DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Phase: N/A

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Igor Koren, MD, MSc, Principal Investigator, Affiliation: Radix - medicinske storitve, Igor Koren s.p.

Summary

We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for asthma in real life conditions. For this purpose we will include both patients that are treated with Symbicort® Turbuhaler® the "classical" maintenance only treatment approach as well as those treated with the SMART approach.

Clinical Details

Official title: Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: to determine the efficacy of both possible treatment approaches with Symbicort® Turbuhaler®, measured by asthma control

Secondary outcome: to determine the number of maintenance and reliever inhalations of Symbicort® Turbuhaler®, as well as the concomitant usage of a separate reliever inhaler even in the case of SMART treatment approach

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- patients diagnosed with persistent asthma treated with Symbicort® Turbuhaler® in line

with its label

- non-pregnant females

- existing maintenance only treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg, 160

μg/4,5 μg or 320 μg/9 μg for at least 1 month

- existing SMART treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg or 160 μg /4,5 μg

for at least 1 month Exclusion Criteria:

- patients not being treated with Symbicort® Turbuhaler®

- patients treated with Symbicort® Turbuhaler® for COPD

Locations and Contacts

Research Site, Celje, Slovenia

Research Site, Domzale, Slovenia

Research Site, Dvorec Sela, Slovenia

Research Site, Grosuplje, Slovenia

Research Site, Idrija, Slovenia

Research Site, Izola, Slovenia

Research Site, Jesenice, Slovenia

Research Site, Kamnik-Duplica, Slovenia

Research Site, Kranj, Slovenia

Research Site, Litija, Slovenia

Research Site, Ljubljana, Slovenia

Research Site, Lucija, Slovenia

Research Site, Maribor, Slovenia

Research Site, Murska Sobota, Slovenia

Research Site, Novo mesto, Slovenia

Research Site, Ptuja, Slovenia

Research Site, Ravne na Koroskem, Slovenia

Research Site, Sezana, Slovenia

Research Site, Slovenj Gradec, Slovenia

Research Site, Slovenska Bistrica, Slovenia

Research Site, Topolsica, Slovenia

Research Site, Velenje, Slovenia

Research Site, Vrhnika, Slovenia

Research Site, Zagorje, Slovenia

Additional Information

Starting date: April 2008
Last updated: July 23, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017